ARS Pharmaceuticals is rated Buy as its current stock price undervalues its pipeline potential despite commercial challenges. Its main product, neffy, an intranasal epinephrine spray, faces slow market adoption and insurance issues but holds promise for significant market share and revenue growth. The company is shifting to a leaner, targeted prescriber strategy aiming to break even by late 2027 while managing high cash burn and debt. The analyst values the stock at $4.61 per share, above the current $3.38, indicating upside potential amid execution and dilution risks.
ARS Pharmaceuticals is the subject of this report; for readers following the health sector, here is Pluang's market snapshot as of Nov 03, 2026 13:11 WIB: Among 150 priced US health-sector stocks, 63 rose and 82 fell today. Notable movers include LQDA at USD 41.71 with a 1-day change of -7.43% and 100% sell order activity, WGS at USD 64.15 down 7.11% with 100% buy order activity, and CLPT at USD 9.96 down 6.83% with 92% sell order activity. The most notable figure is LQDA's 100% sell order activity on Pluang.
ZYT officially introduced its Prax Drive System™, a commercial vehicle technology, partnering with leading Chinese truck makers like XCMG, Shacman, and Sinotruk. The system supports heavy trucks, buses, light trucks, and vans, with production underwa...
Yaoyao, the Asia-Pacific growth lead for the Solana Foundation, has announced her departure after three and a half years with the organization. She joined in 2023 and played a key role in expanding Solana's presence in Greater China, including foundi...
On November 2, spot Bitcoin exchange-traded funds (ETFs) experienced net outflows totaling $399 million, primarily driven by Blackrock's IBIT fund which alone lost $405 million. Despite this, Fidelity's FBTC fund recorded the largest inflow of $6.68 ...
The Rose Income Garden portfolio highlights VICI Properties and W. P. Carey as the most undervalued dividend raisers for October, with VICI offering a 7.52% yield and expanding beyond Las Vegas. The portfolio, which includes 69 investments across all...
U.S. spot Bitcoin and Ether exchange-traded funds (ETFs) experienced combined net outflows of $538.3 million on Monday, with Bitcoin ETFs accounting for $398.6 million and Ether ETFs $139.7 million. This marks a continuation of withdrawals, with Bitc...
